JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)

GENETIC2 trials

Sponsors

Jennerex Biotherapeutics

Conditions

Carcinoma, HepatocellularNeoplasms, Liver

Phase 1

A Study of Recombinant Vaccinia Virus to Evaluate the Safety and Efficacy of a Transdermal Injection Within the Tumor of Patients With Primary or Metastatic Hepatic Carcinoma

CompletedNCT00629759

Jennerex BiotherapeuticsNeoplasms, Liver

Start: 2006-01-01End: 2007-08-01Updated: 2026-05-19

Phase 2

A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma

CompletedNCT00554372

Jennerex BiotherapeuticsCarcinoma, Hepatocellular

Start: 2008-08-01End: 2013-02-01Updated: 2026-06-16

Related Papers

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.

2008-05-19395 citations